

Hitting the right targets : An overview of current ADC trials

Antibody-drug conjugates (ADCs) have revolutionized cancer care over the last decade. Through delivery of DNA or microtubule disrupting chemotherapies, these agents selectively kill cancer cells, while causing minimal damage to healthy cells. Success of ADCs is highlighted by multiple regulatory approvals across the U.S., Europe, Japan and China.

Clinical development remains intense with pivotal trials ongoing across a variety of tumors, against different molecular targets, and with various chemotherapy payloads. Many of the molecular targets are selected due to their exclusive expression on the surface of tumor cells, and/or role as drivers of tumor progression. This gives rise to a multitude of developmental approaches, where some tumors (e.g., breast, lung, and blood tumors) can be targeted via multiple antigens, a single antigen can be targeted across many tumors (i.e., pan-tumor approaches), and the same antigens (e.g., HER2 in breast cancer) can be targeted by the same antibody but with different chemotherapies. Our arsenal of cancer treatment options will certainly expand as a result of these approaches.

Contact Cerner Enviza to learn more about the evolving ADC landscape.

Source: CancerMPact® CancerLandscape, accessed October 1 2022

